StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $59.39 | $64.66 | +8.87% | 1.3M |
| 05-14 | $64.80 | $65.18 | +0.59% | 0.6M |
| 05-15 | $65.00 | $62.48 | -3.88% | 0.7M |
| 05-18 | $63.31 | $62.82 | -0.77% | 0.5M |
| 05-19 | $62.92 | $61.29 | -2.59% | 0.6M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $162.05M | $451.36M | $299.69M | $181.00M |
Operating Income | $-6.12M | $-70.97M | $-62.99M | $-48.46M |
Net Income | $-6.97M | $-66.42M | $-58.05M | $-20.34M |
EPS (Diluted) | $-0.16 | $-1.59 | $-1.40 | $-1.11 |
Total Assets | $581.13M | $562.16M | $534.56M | $494.99M |
Total Liabilities | $232.18M | $218.73M | $199.48M | $162.38M |
Cash & Equivalents | $102.19M | $183.64M | $112.72M | $96.65M |
Free Cash Flow OCF − CapEx | $-30.47M | $-22.31M | $-35.28M | $-51.63M |
Shares Outstanding | 43.02M | 42.55M | 42.45M | 42.21M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.